AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15641037
Drug: Cisplatin 70
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 70 mg/m2 on Day 1 plus gemcitabine 1250 mg/m2 on Days 1 and 8 (PG)
Trial: 15553066
Drug: Combination with
RxNorm normalized name: Iron in combination with folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination with ribavirin
Trial: 15553066
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with PEG-IFN-s
Trial: 10470391
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of droperidol
Trial: 8759084
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg warfarin
Trial: 8759084
Drug: Conventional warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional warfarin therapy
Trial: 25854786
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy + Coenzyme Q10 (CoQ10)
Trial: 11584209
Drug: Glyceryl trinitrate
RxNorm normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glyceryl trinitrate solution (0.025 mg/kg)
Trial: 10561250
Drug: Doxorubicin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (50 mg/m(2) IV over 15 minutes) and docetaxel (75 mg/m(2) IV over 1 hour) every 14 days for four cycles
Trial: 2689679
Drug: Vincristine 2
RxNorm normalized name: vinCRIStine 2 mg/2 mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine 2 mg or vindesine 3 mg per week, prednisolone 20 to 30 mg per day, and partly 6-mercaptopurine 50 to 100 mg, combined with allopurinol 200 to 300 mg per day for 2 to 3 weeks.
Trial: 2689679
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with busulfan or other alkylating agents.
Trial: 5677210
Drug: Diet with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet with tolbutamide, chlorpropamide, or metformin
Trial: 28755104
Drug: Intranasal esketamine
RxNorm normalized name: esketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intranasal esketamine (84 mg)
Trial: 24678955
Drug: Darapladib (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darapladib (160 mg once daily)
Trial: 15792400
Drug: New 625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New 625 mg nelfinavir tablet (test formulation)
Trial: 15792400
Drug: Commercial 250
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial 250 mg nelfinavir tablet (reference formulation)
Trial: 12851606
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy with or without abciximab
Trial: 2196670
Drug: norfloxacin 200
RxNorm normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: norfloxacin 200 mg twice daily for 7 days
Trial: 2196670
Drug: pivmecillinam 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pivmecillinam 200 mg 3 times daily for 7 days
Trial: 351715
Drug: Dopamine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine and prostaglandin A1 administered conjointly
Trial: 28668289
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol 25 μg every 2 h (maximum of 12 doses)
Trial: 28668289
Drug: Transcervical Foley
RxNorm normalized name: CATHETER,FOLEY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcervical Foley catheter (silicone, size 18 F with 30 mL balloon)
Trial: 23828223
Drug: HQK-1001 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HQK-1001 at 30 mg/kg
Trial: 23828223
Drug: HQK-1001 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HQK-1001 at 40 mg/kg
Trial: 23828223
Drug: HQK-1001 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HQK-1001 at 50 mg/kg
Trial: 22859239
Drug: Ustekinumab 45
RxNorm normalized name: USTEKINUMAB 45MG/0.5ML INJ 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab 45 mg at weeks 0, 4, and 16
Trial: 12596623
Drug: One-dose azithromycin
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-dose azithromycin prophylaxis
Trial: 8127110
Drug: Diltiazem (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (0.1 mg/kg per hour)
Trial: 2567150
Drug: Hydroxychloroquine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (400 mg daily for months 0‐6, then 200 mg daily)
Trial: 26545986
Drug: Intensive lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive lipid lowering (target LDL cholesterol <1.4 mmol/L)
Trial: 26545986
Drug: Guideline lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline lipid lowering (target LDL cholesterol <3 mmol/L)
Trial: 3521245
Drug: Control (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (normal saline solution)
Trial: 22475305
Drug: G‐CSF 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF 10 μg/kg/day for 3 days
Trial: 22475305
Drug: Non-G‐CSF group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-G‐CSF group
Trial: 17165082
Drug: Verapamil hydrochloride
RxNorm normalized name: Verapamil Hydrochloride
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil hydrochloride (isoptin 240 mg KKH tablets, oral t.i.d.)
Trial: 12174946
Drug: Sequential Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Doxorubicin (A) -> Docetaxel (T) -> CMF
Trial: 12174946
Drug: Sequential accelerated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential accelerated A -> T -> CMF
Trial: 12174946
Drug: Combination therapy:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy: A 50 mg/m2 + T 75 mg/m2 q 3 wks x 4, followed by CMF x 4
Trial: 12174946
Drug: Sequential T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential T -> A -> CMF
Trial: 8655009
Drug: Antinuclear antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antinuclear antibodies (ANA) detected in women with endometriosis
Trial: 8655009
Drug: Antinuclear antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antinuclear antibodies (ANA) detected in women with idiopathic infertility
Trial: 8655009
Drug: Antinuclear antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antinuclear antibodies (ANA) detected in women with hypothalamic‐pituitary dysfunction
Trial: 8655009
Drug: Antinuclear antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antinuclear antibodies (ANA) detected in healthy nonpregnant women
Trial: 7433479
Drug: Cinnarizine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnarizine (75 mg 3-times daily)
Trial: 31753880
Drug: Mindful Eating
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mindful Eating (ME) + Treatment as Usual (TAU)
Trial: 25765294
Drug: Bimatoprost 0.03%
RxNorm normalized name: BIMATOPROST 0.03% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimatoprost 0.03% solution twice daily for 3 months
Trial: 25765294
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate 0.1% cream once daily for 3 months
Trial: 23389755
Drug: gabapentin (GBP;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gabapentin (GBP; up to 1,200 mg for 39 days) and flumazenil (FMZ) infusions (2 days)
Trial: 20008239
Drug: Monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies and dose‐intensified approaches including autologous stem cell transplantation (ASCT) strategies
Trial: 20008239
Drug: Emerging strategies
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emerging strategies such as proteasome inhibitors, IMIDs, mTOR inhibitors
Trial: 20008239
Drug: Combination strategies
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination strategies currently being investigated in numerous trials
Trial: 18041162
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors and/or ARBs
Trial: 9164362
Drug: Ipratropium nasal
RxNorm normalized name: ipratropium nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipratropium nasal spray (42 micrograms per nostril, administered twice daily for 4 weeks)
Trial: 9164362
Drug: Placebo nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray (administered twice daily for 4 weeks)
Trial: 3652627
Drug: Deferoxamine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferoxamine therapy (1 to 6 g intravenously once a week for a mean duration of 7.6 +/- 3.3 months)
Trial: 3652627
Drug: Deferoxamine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferoxamine therapy
Trial: 20598832
Drug: Integrated Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated Cognitive Behavioral Therapy (ICBT)
Trial: 23583219
Drug: Digoxin antibody
RxNorm normalized name: digoxin antibodies Fab fragments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin antibody fragment (DIF)
Trial: 15673100
Drug: 6% carbohydrate-electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% carbohydrate-electrolyte (CHO-E) solution
Trial: 15661816
Drug: Acetylcholine (ACh)
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylcholine (ACh) infusion (137.5 mum)
Trial: 15661816
Drug: Acetylcholine (ACh)
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylcholine (ACh) infusion (137.5 mum) with NOS inhibition (10 mm l-NAME)
Trial: 15661816
Drug: Acetylcholine (ACh)
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylcholine (ACh) infusion (137.5 mum) with COX inhibition (10 mm ketorolac)
Trial: 15661816
Drug: Acetylcholine (ACh)
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylcholine (ACh) infusion (137.5 mum) with NOS and COX inhibition
Trial: 7864705
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate 1.2 g over 20 minutes after albuterol treatment
Trial: 6185343
Drug: Intra-arterial infusion
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial infusion of methotrexate (MTX) 500 mg over 10 days
Trial: 6185343
Drug: Intra-arterial infusion
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial infusion of bleomycin (BLM) 95 mg over 13 days
Trial: 30613078
Drug: Low intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intensity ultrasound (LIUS) and traditional exercise therapy (TET)
Trial: 30613078
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser therapy (LLLT) and traditional exercise therapy (TET)
Trial: 30613078
Drug: Traditional exercise
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional exercise therapy (TET)
Trial: 25074351
Drug: ibandronate 150
RxNorm normalized name: ibandronate 150 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibandronate 150 mg/month
Trial: 25074351
Drug: alendronate 70
RxNorm normalized name: ALENDRONATE 70MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alendronate 70 mg/week
Trial: 25074351
Drug: risedronate 35
RxNorm normalized name: risedronate 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: risedronate 35 mg/week
Trial: 25074351
Drug: oral bisphosphonates
RxNorm normalized name: methylene diphosphonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral bisphosphonates (all three types)
Trial: 19885413
Drug: Test implants
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test implants (thin mucosa, group A)
Trial: 19885413
Drug: Test implants
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test implants (thick mucosa, group B)
Trial: 10723632
Drug: Flumazenil 2
RxNorm normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flumazenil 2 mg/20 ml
Trial: 10723632
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo infusions
Trial: 8704691
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (BEAM regimen) followed by autologous bone marrow and/or peripheral blood progenitor cell (PBPC) rescue
Trial: 6361558
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (3 mg/kg initial dose)
Trial: 25029202
Drug: Calcitriol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol (2 μg intravenously)
Trial: 20385996
Drug: Short-course intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course intensive polychemotherapy (in blocks R1, R2, or R3) and cranial/craniospinal irradiation followed by maintenance therapy.
Trial: 17288680
Drug: Aspirin 30-325
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 30-325 mg daily
Trial: 2273193
Drug: 0.6 mg
RxNorm normalized name: thymol 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg riboflavin daily
Trial: 2273193
Drug: 1.2 mg
RxNorm normalized name: RNA 1.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mg riboflavin daily
Trial: 2273193
Drug: 1.7 mg
RxNorm normalized name: pectin 1.7 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.7 mg riboflavin (one-a-day supplement)
Trial: 31618905
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of BB536 and AHCC®
Trial: 21888870
Drug: Zednad® Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zednad® Tablet (500 mg cefuroxime/tablet)
Trial: 21888870
Drug: Zinnat® Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinnat® Tablet (500 mg cefuroxime/tablet)
Trial: 19055515
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose aspirin
Trial: 19055515
Drug: Both aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both aspirin combined groups
Trial: 19055515
Drug: Aspirin groups
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin groups (without considering dose)
Trial: 16738974
Drug: Antiemetic drugs
RxNorm normalized name: metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antiemetic drugs (groups 1 to 6)
Trial: 1550911
Drug: Intravenous levoprotiline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous levoprotiline (15 mg)
Trial: 1550911
Drug: Peroral levoprotiline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peroral levoprotiline (75 mg)
Trial: 3933019
Drug: cream containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cream containing l‐cysteine, glycine and dl‐threonine
Trial: 3933019
Drug: cream base
RxNorm normalized name: Cream Base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cream base alone (placebo)
Trial: 30967424
Drug: Low-dose anti-thymocyte
RxNorm normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose anti-thymocyte globulin (ATG) (2.5 mg/kg)
Trial: 27556735
Drug: Modeling counts
RxNorm normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Modeling counts of golden eagles using distance sampling and visual mark-recapture procedures; no specific dosage or duration mentioned as this is observational modeling.
Trial: 27556735
Drug: Model predictions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model predictions of habitat use based on survey data from 2006-2010; no specific dosage or duration mentioned.
Trial: 27556735
Drug: Map predicting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Map predicting intensity of use by golden eagles during late summer across a ∼2 million‐km2 study area; no specific dosage or duration mentioned.
Trial: 17344605
Drug: Computerized pelvis
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized pelvis traction, ultrashort wave, and traditional Chinese medicine iontophoresis
Trial: 15695300
Drug: Once-weekly oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly oral alendronate (1-2 mg/kg body weight)
Trial: 11876712
Drug: Tetracycline-containing therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline-containing therapy (omeprazole 20 mg twice daily, bismuth 120 mg four times daily, metronidazole 500 mg twice daily, tetracycline 500 mg four times daily for 7 days)
Trial: 11876712
Drug: Clarithromycin-containing therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin-containing therapy (omeprazole 20 mg twice daily, bismuth 120 mg four times daily, metronidazole 500 mg twice daily, clarithromycin 500 mg twice daily for 7 days)
Trial: 12577331
Drug: Composite Salviae
RxNorm normalized name: Salvia sclarea seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite Salviae Injection (CSI) 0.5 ml/kg by intravenous dripping
Trial: 9756307
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined (cc) 2 mg oestradiol valerate and 0.7 mg norethisterone acetate HRT daily
Trial: 10151073
Drug: Rhinopront syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhinopront syrup (15 g)
Trial: 10151073
Drug: Triaminic (commercial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triaminic (commercial standard decongestant)
Trial: 10151073
Drug: Rhinopront syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhinopront syrup (1 g per year of age)
Trial: 30246187
Drug: Supracrestal implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supracrestal implants (SC)
Trial: 30246187
Drug: Bone level
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone level implants (BL)
Trial: 26330288
Drug: Adjunctive armodafinil
RxNorm normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive armodafinil 150 mg/day
Trial: 25933099
Drug: Adjunctive armodafinil
RxNorm normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive armodafinil 200 mg/day
Trial: 19058484
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (two drops in growing concentrations of 500, 1,000, 2,000, 10,000, and 20,000 biological units)
Trial: 10913779
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of NSAIDs (diclofenac sodium salt, fenoprofen calcium salt, ibuprofen, ketoprofen, nabumetone, sulindac)
Trial: 10913779
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of antimicrobial drugs (acyclovir, ampicillin, atovaquone, dapsone, enoxacin, ethambutol, lomefloxacin HCl, ofloxacin, pentamidine isethionate, pyrimethamine, sulfamethoxazole, tetracycline HCl, trimethoprim)
Trial: 10913779
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of drugs
Trial: 8807660
Drug: Fluvoxamine 50
RxNorm normalized name: fluvoxamine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine 50 mg per day for 4 days and 100 mg per day for 8 days
Trial: 8807660
Drug: Caffeine 200
RxNorm normalized name: caffeine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 200 mg orally
Trial: 1564678
Drug: Triphasic oral
RxNorm normalized name: CeeNU, triphasic oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic oral contraceptive (o.c.)
Trial: 31999489
Drug: RT+LP‐L (1.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT+LP‐L (1.7 mg/kg, low dosage of LP)